Hydroxychloroquine News and Research

RSS

Cardiovascular adverse events linked to hydroxychloroquine and chloroquine

As the antimalarial drugs hydroxychloroquine and chloroquine have drawn attention as potential therapies for COVID-19 and are being widely used off-label, it's now more important than ever to have a thorough assessment of the safety of these medications.

23 Sep 2020

Scientists investigate active plasma metabolite of remdesivir in SARS-CoV-2 mouse model

Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.

20 Sep 2020

Azelastine antihistamine inhibits SARS-CoV-2 infection in nasal tissue in vitro

In a study published on the bioRxiv preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.

16 Sep 2020

Azithromycin use for treating COVID-19 may increase risk of cardiac events

Debates over whether hydroxychloroquine should be taken to help lessen the duration and impact of COVID-19 have revolved around the drug's reputation for causing cardiac events such as abnormal heart rhythms or beats and cardiac arrest.

16 Sep 2020

AI and machine learning tools can help separate COVID-related claims

As the COVID-19 pandemic has swept the world, researchers have published hundreds of papers each week reporting their findings - many of which have not undergone a thorough peer review process to gauge their reliability.

16 Sep 2020

Can amodiaquine short circuit this pandemic?

A recent study by the US researchers highlights the value of the human organ chip technology as a more robust and physiologically relevant platform for rapid drug repurposing, and suggest that amodiaquine may be used to prevent the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2020

Identifying, preventing and treating drug-induced arrhythmias

Health care professionals should become more familiar with medications that cause irregular heart rhythms called arrhythmias, according to "Drug- Induced Arrhythmias," a new scientific statement from the American Heart Association, published today in the Association's flagship journal Circulation.

15 Sep 2020

Most adults wary of taking any vaccine approved before the election

The public is deeply skeptical about any coronavirus vaccine approved before the November election, and only 42% would be willing to get a vaccine in that scenario, according to a new poll.

10 Sep 2020

Intravenous iron therapy does not benefit anemic patients during surgery, study finds

A global study led by researchers at The University of Western Australia has addressed the rising use of intravenous iron therapy in anemic patients during major surgery and found there is little benefit.

10 Sep 2020

Dozens of U.S. hospitals poised to defy FDA’s directive on COVID plasma

Dozens of major hospitals across the U.S. are grappling with whether to ignore a federal decision allowing broader emergency use of blood plasma from recovered COVID patients to treat the disease in favor of dedicating their resources to a gold-standard clinical trial that could help settle the science for good.

3 Sep 2020

14 existing drugs identified as SARS-CoV-2 main protease inhibitors

Now, a new study published on the preprint server bioRxiv in August 2020 reports on the identification of 14 compounds that can inhibit the key viral enzyme called the Main Protease (MPro) at micromolar concentrations.

1 Sep 2020

Researchers propose new reforms to improve transparency of drug authorizations

On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use of hydroxychloroquine for the treatment of COVID-19. On June 15, after a number of studies failed to find positive effects, the agency revoked this authorization.

1 Sep 2020

Study shows how genetics could improve safety and efficacy of drugs for COVID-19 treatment

Over the past few months, a number of drugs have been under investigation to treat COVID-19 without well-established safety or data to support these claims.

28 Aug 2020

Study: Hydroxychloroquine plus azithromycin linked to significant cardiovascular risks

The combination of hydroxychloroquine (HCQ) and azithromycin (AZM) has been linked to significant cardiovascular risks, including mortality, in the largest safety study ever performed on both HCQ and HCQ+AZM.

25 Aug 2020

Hydroxychloroquine treatment for COVID-19 patients lowers in-hospital mortality rates

An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

25 Aug 2020

Evaluating the use of sofosbuvir and daclatasvir for treatment of COVID-19

Several new papers in Journal of Antimicrobial Chemotherapy, published by Oxford University Press, suggest successful treatments for COVID-19.

24 Aug 2020

Study reveals important trends in early COVID-19 patients in Massachusetts

Data from the first COVID-19 patients treated at three large Massachusetts hospitals reveal important trends, including disproportionate representation of vulnerable populations, high rates of disease-related complications, and the need for post-discharge, post-acute care and monitoring.

19 Aug 2020

Hydroxychloroquine is not a possible defense against COVID-19, study shows

Researchers at Case Western Reserve University have added to the growing body of understanding about how hydroxychloroquine (HCQ) is not a possible defense against COVID-19.

17 Aug 2020

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and cause disease and death in many countries even today. At present, there is no effective treatment. A recent study published on the preprint server bioRxiv in August 2020 reports the potential of a new class of drugs called CAR NK cells, which could be used off-the-shelf to treat this disease.

17 Aug 2020

Cardiovascular disease in COVID-19

The current COVID-19 pandemic is a primarily respiratory illness, manifesting with severe hypoxia and often progressing to acute respiratory distress syndrome (ARDS) and death. However, it is also known to be linked to a wide range of cardiovascular (CV) manifestations that are associated with a very poor prognosis.

13 Aug 2020